Extending survival for people with hepatitis C using tobacco dependence treatment

Coral Gartner; Alleshia Miller; Billie Bonevski

doi:10.1016/S0140-6736(17)32460-1

Extending survival for people with hepatitis C using tobacco dependence treatment

Coral Gartner, Alleshia Miller, Billie Bonevski

Research output: Contribution to journal › Letter › peer-review

7 Citations (Scopus)

Abstract

The availability of direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) has led WHO to advocate for the elimination of HCV. However, a 2017 Cochrane review1 suggests that DAA treatment might not improve morbidity and mortality in people living with HCV: trials have shown no benefit on these endpoints, despite a sustained virological response. Stefan Wiktor and John Scott (July 8, p 107)2 state that longer term observational data are needed to assess mortality in people receiving DAA treatment for HCV.

Original language	English
Pages (from-to)	2033
Number of pages	1
Journal	The Lancet
Volume	390
Issue number	10107
DOIs	https://doi.org/10.1016/S0140-6736(17)32460-1
Publication status	Published - 4 Nov 2017
Externally published	Yes

Keywords

hepatitis C
tobacco dependence
HIV
HCV
direct-acting antiviral
DAA
treatment
virological

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0140-6736(17)32460-1Licence: In Copyright

Cite this

@article{dbe986b57fbd4b31bae1ad33acf492fa,

title = "Extending survival for people with hepatitis C using tobacco dependence treatment",

abstract = "The availability of direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) has led WHO to advocate for the elimination of HCV. However, a 2017 Cochrane review1 suggests that DAA treatment might not improve morbidity and mortality in people living with HCV: trials have shown no benefit on these endpoints, despite a sustained virological response. Stefan Wiktor and John Scott (July 8, p 107)2 state that longer term observational data are needed to assess mortality in people receiving DAA treatment for HCV.",

keywords = "hepatitis C, tobacco dependence, HIV, HCV, direct-acting antiviral, DAA, treatment, virological",

author = "Coral Gartner and Alleshia Miller and Billie Bonevski",

year = "2017",

month = nov,

day = "4",

doi = "10.1016/S0140-6736(17)32460-1",

language = "English",

volume = "390",

pages = "2033",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Lancet",

number = "10107",

}

TY - JOUR

T1 - Extending survival for people with hepatitis C using tobacco dependence treatment

AU - Gartner, Coral

AU - Miller, Alleshia

AU - Bonevski, Billie

PY - 2017/11/4

Y1 - 2017/11/4

N2 - The availability of direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) has led WHO to advocate for the elimination of HCV. However, a 2017 Cochrane review1 suggests that DAA treatment might not improve morbidity and mortality in people living with HCV: trials have shown no benefit on these endpoints, despite a sustained virological response. Stefan Wiktor and John Scott (July 8, p 107)2 state that longer term observational data are needed to assess mortality in people receiving DAA treatment for HCV.

AB - The availability of direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) has led WHO to advocate for the elimination of HCV. However, a 2017 Cochrane review1 suggests that DAA treatment might not improve morbidity and mortality in people living with HCV: trials have shown no benefit on these endpoints, despite a sustained virological response. Stefan Wiktor and John Scott (July 8, p 107)2 state that longer term observational data are needed to assess mortality in people receiving DAA treatment for HCV.

KW - hepatitis C

KW - tobacco dependence

KW - HIV

KW - HCV

KW - direct-acting antiviral

KW - DAA

KW - treatment

KW - virological

UR - http://www.scopus.com/inward/record.url?scp=85032692120&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(17)32460-1

DO - 10.1016/S0140-6736(17)32460-1

M3 - Letter

C2 - 29115237

AN - SCOPUS:85032692120

SN - 0140-6736

VL - 390

SP - 2033

JO - The Lancet

JF - The Lancet

IS - 10107

ER -

Extending survival for people with hepatitis C using tobacco dependence treatment

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this